Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats.
BACKGROUND
The role played by endogenous opioids in mediating the reinforcing properties of nicotine is unclear. As with preclinical studies, clinical trials with naloxone, a prototypic opioid receptor antagonist have yielded equivocal findings with regard to its efficacy in reducing cigarette smoking.


OBJECTIVE
The aim of the present study was to examine the effects of three opioids that exhibit relative selectivity at mu-, kappa- and delta-opioid receptors on nicotine self-administration in male hooded Lister rats.


METHODS
Graded doses (0.3, 1.0, and 3.0 mg/kg IP) of each opioid agonist or antagonist were tested in different groups of rats repeatedly over three consecutive nicotine intravenous nicotine-self administration (0.03 mg/kg/infusion) sessions. The same treatments were tested in parallel groups of rats trained to respond for food reinforcement.


RESULTS
Naloxone was very effective in attenuating the levels of nicotine self-administered across all doses tested. The selective kappa-opioid receptor agonist U50,488, reduced nicotine self-administration in doses of 1 and 3 mg/kg, while the 0.3 mg/kg dose produced a small increase in nicotine intake. Finally, the specific delta-opioid receptor antagonist, naltrindole did not significantly modify nicotine self-administration behaviour. In contrast, all three opioids failed to modify behaviour maintained by food reinforcement.


CONCLUSIONS
These findings suggest endogenous opioids are crucial in mediating the reinforcing effects of nicotine and that the mu-opioid receptor subtype may represent a potential target for selectively reducing nicotine-taking behaviour as part of a pharmacological approach to develop smoking cessation aids.
Ismayilova
Naila
N
Psychobiology Research Laboratories, Institute of Neuroscience, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
Shoaib
Mohammed
M
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists; D009538:Nicotine / Q000008:administration & dosage*; D051381:Rats; D011957:Receptors, Opioid / Q000819:agonists*; D017465:Receptors, Opioid, delta / Q000819:agonists / Q000037:antagonists & inhibitors; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000037:antagonists & inhibitors; D012646:Self Administration; D014029:Tobacco Use Disorder / Q000503:physiopathology / Q000523:psychology*
D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009270:Naloxone; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D009538:Nicotine; C055382:naltrindole
Neurosci Lett. 2002 Apr 26;323(2):164-6
11950518
Life Sci. 1980 Oct 27;27(17):1541-5
7003284
J Pharmacol Exp Ther. 1971 Nov;179(2):268-76
5002481
Psychopharmacology (Berl). 1989;99(4):473-8
2594913
Psychopharmacology (Berl). 2009 Mar;202(4):589-98
18807246
J Pharmacol Exp Ther. 1988 Mar;244(3):1067-80
2855239
Nature. 1985 Apr 11-17;314(6011):533-4
2986002
Neuropharmacology. 2000 Oct;39(13):2848-55
11044755
J Pharmacol Exp Ther. 1995 Oct;275(1):150-63
7562544
Arch Gen Psychiatry. 1999 Jul;56(7):663-8
10401515
Neuron. 2005 Jun 16;46(6):933-43
15953421
Neuropsychopharmacology. 2007 Feb;32(2):450-7
17091130
Nicotine Tob Res. 2005 Dec;7(6):901-7
16298725
Brain Res. 1988 Dec 6;474(2):364-8
2463060
Psychopharmacology (Berl). 2004 Mar;172(2):179-86
14610636
Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50
1347943
Eur J Pharmacol. 1994 Dec 27;271(2-3):461-9
7705446
Pharmacol Biochem Behav. 1993 Nov;46(3):527-34
8278429
J Subst Abuse. 1988-1989;1(2):153-9
2980866
Psychopharmacology (Berl). 1995 Dec;122(4):390-94
8657839
Psychopharmacology (Berl). 1988;96(1):29-35
2852377
Psychopharmacology (Berl). 2006 Mar;184(3-4):266-72
16088413
Psychopharmacology (Berl). 1997 Jan;129(1):35-43
9122361
Behav Pharmacol. 1995 Mar;6(2):99-106
11224316
J Pharmacol Exp Ther. 1991 Feb;256(2):500-5
1847197
Pharmacol Biochem Behav. 1997 Feb;56(2):167-73
9050071
Psychopharmacology (Berl). 1985;86(3):281-5
2863837
Nicotine Tob Res. 1999 Mar;1(1):11-20
11072385
Addiction. 1999 Aug;94(8):1227-37
10615738
Pharmacol Biochem Behav. 2004 Apr;77(4):711-5
15099916
Pharmacol Rev. 1975 Sep;27(3):397-406
817310
Trends Pharmacol Sci. 1991 Dec;12(12):467-73
1792691
J Pharmacol Exp Ther. 1976 Feb;196(2):298-306
815542
Psychopharmacology (Berl). 1995 Jan;117(1):2-10; discussion 14-20
7724697
Psychopharmacology (Berl). 1992;107(2-3):285-9
1615127
Eur J Pharmacol. 1996 Mar 18;298(3):207-16
8846818
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
2899326
J Neurosci. 2005 Feb 2;25(5):1103-12
15689546
Trends Pharmacol Sci. 2004 Jan;25(1):42-8
14723978
Pharmacol Biochem Behav. 1988 May;30(1):227-34
3051048
Psychopharmacology (Berl). 2006 Mar;184(3-4):353-66
16240165
Neuropharmacology. 2008 Feb;54(2):438-44
18054052
Pharmacol Biochem Behav. 1995 Jan;50(1):91-6
7700960
J Pharmacol Exp Ther. 1993 Feb;264(2):648-53
7679733
Behav Neurosci. 1995 Feb;109(1):91-105
7734084
J Med Chem. 1990 Jun;33(6):1714-20
2160538
Pharmacol Biochem Behav. 2001 Dec;70(4):515-30
11796151
Brain Res Brain Res Rev. 2005 Feb;48(1):74-97
15708629
Pharmacol Biochem Behav. 2000 Jul;66(3):563-72
10899371
Neurosci Lett. 1994 Nov 7;181(1-2):57-60
7898771
Oncogene. 2002 Oct 21;21(48):7326-40
12379876
Psychopharmacology (Berl). 1995 Aug;120(4):418-25
8539322
Psychopharmacology (Berl). 2000 Apr;149(2):107-14
10805604
Psychopharmacology (Berl). 1986;89(3):261-4
3088648
Psychopharmacology (Berl). 1991;104(2):167-70
1876660